Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.06 +2.0%	$1.82	$1.43 ▼ $4.26	$207.85M	1.62	144,985 shs	113,290 shs
ASMB Assembly Biosciences	$18.15 -0.8%	$14.99	$7.75 ▼ $19.93	$138.55M	0.62	27,602 shs	15,693 shs
CYDY CytoDyn	$0.29 +5.6%	$0.34	$0.10 ▼ $0.49	$356.69M	1.17	1.38 million shs	413,710 shs
MIST Milestone Pharmaceuticals	$1.93 +0.7%	$1.56	$0.63 ▼ $2.75	$103.72M	0.96	955,072 shs	237,742 shs
PRTA Prothena	$6.47 +2.4%	$6.40	$4.32 ▼ $25.42	$346.38M	0.01	798,449 shs	636,811 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	0.00%	+2.49%	+19.08%	+24.10%	-45.93%
ASMB Assembly Biosciences	0.00%	+4.85%	+14.80%	+108.38%	+49.38%
CYDY CytoDyn	0.00%	+10.68%	-16.54%	+35.07%	+109.87%
MIST Milestone Pharmaceuticals	0.00%	+3.98%	+11.15%	+177.99%	+45.96%
PRTA Prothena	0.00%	+6.41%	+27.87%	-40.42%	-67.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACIU AC Immune	2.4456 of 5 stars	3.5	3.0	0.0	0.0	2.0	0.8	0.6
ASMB Assembly Biosciences	3.6613 of 5 stars	3.3	3.0	0.0	4.7	1.7	0.0	0.0
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.2979 of 5 stars	3.2	5.0	0.0	0.0	0.0	2.5	0.0
PRTA Prothena	3.0729 of 5 stars	4.2	2.0	0.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	3.00	Buy	$12.00	482.52% Upside
ASMB Assembly Biosciences	2.67	Moderate Buy	$33.00	81.82% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	261.94% Upside
PRTA Prothena	2.33	Hold	$31.50	386.86% Upside

Current Analyst Ratings Breakdown

Latest ACIU, MIST, ASMB, CYDY, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00
5/27/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/13/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$28.30M	7.31	N/A	N/A	$1.29 per share	1.60
ASMB Assembly Biosciences	$28.52M	4.86	N/A	N/A	$5.25 per share	3.46
CYDY CytoDyn	N/A	N/A	N/A	N/A	($0.11) per share	N/A
MIST Milestone Pharmaceuticals	$1M	103.39	N/A	N/A	$0.25 per share	7.74
PRTA Prothena	$135.16M	2.58	N/A	N/A	$9.05 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-177.79%	-44.60%	-22.25%	8/5/2025 (Estimated)
ASMB Assembly Biosciences	-$40.18M	-$6.23	N/A	N/A	N/A	-124.15%	-131.77%	-36.81%	8/6/2025 (Estimated)
CYDY CytoDyn	-$49.84M	N/A	0.00	∞	N/A	N/A	N/A	-33.26%	8/14/2025 (Estimated)
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)

Latest ACIU, MIST, ASMB, CYDY, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/8/2025	Q1 2025	ASMB Assembly Biosciences	-$2.01	-$1.17	+$0.84	-$1.17	$7.41 million	$9.42 million
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
4/30/2025	Q1 2025	ACIU AC Immune	-$0.22	-$0.21	+$0.01	-$0.21	$1.99 million	$1.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	N/A	1.53	1.53
ASMB Assembly Biosciences	N/A	2.05	2.05
CYDY CytoDyn	N/A	0.30	0.30
MIST Milestone Pharmaceuticals	4.06	4.67	4.67
PRTA Prothena	N/A	9.00	9.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
ASMB Assembly Biosciences	19.92%
CYDY CytoDyn	5.06%
MIST Milestone Pharmaceuticals	86.18%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
ASMB Assembly Biosciences	5.30%
CYDY CytoDyn	0.54%
MIST Milestone Pharmaceuticals	19.50%
PRTA Prothena	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
ASMB Assembly Biosciences	100	7.64 million	7.23 million	Optionable
CYDY CytoDyn	20	1.25 billion	1.24 billion	Not Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable

ACIU, MIST, ASMB, CYDY, and PRTA Headlines

Recent News About These Companies

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

July 4 at 2:56 PM | zacks.com

Prothena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average - Should You Sell?

July 4 at 4:55 AM | marketbeat.com

Prothena Corporation plc (NASDAQ:PRTA) Receives $31.50 Average PT from Analysts

June 30, 2025 | americanbankingnews.com

Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts

June 25, 2025 | marketbeat.com

Prothena Corp (PRTA) Receives Reiterated Neutral Rating from Cantor Fitzgerald | PRTA Stock News

June 20, 2025 | gurufocus.com

Cantor Fitzgerald Reiterates "Neutral" Rating for Prothena (NASDAQ:PRTA)

June 20, 2025 | marketbeat.com

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)

June 19, 2025 | finance.yahoo.com

Prothena Announces Corporate Restructuring

June 18, 2025 | finance.yahoo.com

Prothena (NASDAQ:PRTA) Shares Pass Below 200 Day Moving Average - Time to Sell?

June 18, 2025 | marketbeat.com

Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)

June 17, 2025 | msn.com

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

June 16, 2025 | uk.finance.yahoo.com

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

June 16, 2025 | businesswire.com

Prothena Co. plc (NASDAQ:PRTA) Short Interest Down 50.7% in May

June 14, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Prothena FY2026 Earnings

June 10, 2025 | marketbeat.com

PRTA Prothena Corporation plc

June 7, 2025 | seekingalpha.com

Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation

May 30, 2025 | msn.com

Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure

May 30, 2025 | msn.com

H.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PT

May 30, 2025 | insidermonkey.com

Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform

May 30, 2025 | finance.yahoo.com

B of A Securities Downgrades Prothena (PRTA)

May 29, 2025 | msn.com

Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results

May 28, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU, MIST, ASMB, CYDY, and PRTA Company Descriptions

AC Immune NASDAQ:ACIU

$2.06 +0.04 (+1.98%)

Closing price 07/3/2025 02:31 PM Eastern

Extended Trading

$2.06 0.00 (0.00%)

As of 07/3/2025 04:51 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Assembly Biosciences NASDAQ:ASMB

$18.15 -0.15 (-0.82%)

As of 07/3/2025 01:04 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

CytoDyn OTCMKTS:CYDY

$0.29 +0.02 (+5.56%)

As of 07/3/2025 12:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Milestone Pharmaceuticals NASDAQ:MIST

$1.93 +0.01 (+0.73%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$1.92 -0.01 (-0.72%)

As of 07/3/2025 04:43 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Prothena NASDAQ:PRTA

$6.47 +0.15 (+2.37%)

Closing price 07/3/2025 03:46 PM Eastern

Extended Trading

$6.41 -0.06 (-0.94%)

As of 07/3/2025 04:52 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time